Keywords: Kyowa Hakko Kirin, ARQ197, Tivantinib, NSCLC, Ph III, Asia, ArQule
Kyowa Hakko Kirin starts Ph III trial of ARQ 197 (tivantinib) in NSCLC patients in Asia
Article | 10 August 2011
Japanese drugmaker Kyowa Hakko Kirin (TYO: 4151) says it has initiated an international Phase III clinical study evaluating the combination of ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
- Additional indications in Japan for Roche's Avastin and Astellas' Prograf
- US Supreme Court says patent settlement can "sometimes" be illegal
